Tony Cates joins Cycle Group Holdings Board of Directors
October 6th 2021
Tony Cates joins Cycle Group Holdings Board of Directors
Cambridge, UK, 6th October 2021: Cycle Group Holdings, the holding company of Cycle Pharmaceuticals (a leading commercial-stage rare disease pharmaceuticals business) and Varsity Pharmaceuticals (a pre-clinical oncology pharmaceuticals business), today announced that Tony Cates has agreed to join the Board of Directors as a Non-Executive Director and Chair of the Audit & Risk Committee.
Tony brings a wealth of experience to the role. Tony retired from KPMG in 2021 following a distinguished career at this Big 4 professional services firm. Tony was a Vice Chair and Board Member of KPMG LLP including Chair of the Audit Committee and Chair of the Risk Committee. Tony was also Chair of the Audit Board – overseeing the ring-fenced audit business of KPMG LLP. Tony has also held positions as Chair of the KPMG Foundation and the KPMG Alumni Programme. Tony’s executive career at KPMG included being Head of the International Markets & Government business, Head of KPMG Audit, Chief Operating Officer of KPMG LLP and lead audit partner for several FTSE100 clients.
“Cycle’s pharmaceutical products treat some of the most fragile members of our community – children born with life-threatening genetic conditions. I am delighted to be joining the Board of a company whose mission is to improve the quality of life of rare disease patients. Cycle is uniquely positioned to continue its growth trajectory by launching additional drug products and I look forward to bringing my experience to this role as the company continues to grow,” commented Tony. “Varsity’s partnerships with world-leading oncologists also give hope to a future of addressing treatment-resistant cancers.”
About Cycle Pharmaceuticals
Cycle Pharmaceuticals was founded in 2012 with the sole aim of delivering best-in-class drug treatments and product support to the under-served rare disease patient community. Cycle focuses on rare metabolic, immunological, and neurological genetic conditions. Cycle is headquartered in Cambridge, UK and has offices in Boston, Massachusetts. For more information, please visit www.cyclepharma.com and follow us on Twitter, LinkedIn, Facebook and Instagram.
About Varsity Pharmaceuticals
Varsity Pharmaceuticals partners with leading oncology academics in Cambridge, and globally, to identify new targets to address drug resistance and develop new small molecule therapies for several resistant cancers. Varsity works to transform these novel discoveries into new therapies for patients by supporting the clinical development work needed for their eventual regulatory approval and distribution. For more information, please visit www.varsitypharma.com.